Access cutting-edge autoimmune disease treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Access autoimmune disease specialists in Indianapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related autoimmune disease treatment provided free
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this autoimmune disease clinical trial in Indianapolis, IN
If you're searching for autoimmune disease treatment options in Indianapolis, IN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced autoimmune disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.